Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H30N2O2.C7H8O3S |
| Molecular Weight | 526.687 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=C(C=C1)S(O)(=O)=O.CC2(C)C(C(=O)C3=CN(CCN4CCOCC4)C5=C3C=CC=C5)C2(C)C
InChI
InChIKey=PJYFREAJNFLEMS-UHFFFAOYSA-N
InChI=1S/C22H30N2O2.C7H8O3S/c1-21(2)20(22(21,3)4)19(25)17-15-24(18-8-6-5-7-16(17)18)10-9-23-11-13-26-14-12-23;1-6-2-4-7(5-3-6)11(8,9)10/h5-8,15,20H,9-14H2,1-4H3;2-5H,1H3,(H,8,9,10)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17994110
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17994110
A-796260 is a compound that acts as a potent and selective cannabinoid CB2 receptor agonist. The analgesic effects of A-796260 on activity-induced pain behavior were evaluated in a rat model, the results demonstrated that A-796260 may be a useful new pharmacological compound for further studying CB2 receptor pharmacology and for evaluating its role in the modulation of pain.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P34972 Gene ID: 1269.0 Gene Symbol: CNR2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19921781 |
0.77 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17994110
Neuropathic pain model in rats: The analgesic effects of A-796260 on activity-induced pain behaviour were evaluated in a rat model of sodium monoiodoacetate (MIA)-induced osteoarthritic (OA) joint pain, observed 20 days following the i.a. injection of MIA. A-796260 demonstrated dose-related (3.5-35 mg/kg) reversal of activity-induced pain behaviour in osteoarthritic (OA) rats with effects comparable to celecoxib (38 mg kg−1 i.p.), a clinically relevant analgesic for OA pain.
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17994110
The receptor-binding potencies of A-796260 was determined in [3H]-CP 55,940 competition binding assays performed with membrane preparations generated from recombinant cell lines expressing the human CB1, human CB2, rat CB1 or rat CB2 receptors. A-796260 exhibited high binding potencies at both human and rat CB2 receptors with Ki values of 4.37 and 13.0 nM, respectively
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
RNP93O79DW
Created by
admin on Mon Mar 31 22:10:27 GMT 2025 , Edited by admin on Mon Mar 31 22:10:27 GMT 2025
|
PRIMARY | |||
|
11584524
Created by
admin on Mon Mar 31 22:10:27 GMT 2025 , Edited by admin on Mon Mar 31 22:10:27 GMT 2025
|
PRIMARY | |||
|
895155-27-8
Created by
admin on Mon Mar 31 22:10:27 GMT 2025 , Edited by admin on Mon Mar 31 22:10:27 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD